FTO and acute myeloid leukemia: These were tested on AML cells, and showed promising results in suppressing proliferation and proapoptotic effects.[139] Further optimization of FB23 and FB23‐2 led to the development of a more potent FTO inhibitor, Dac51, which enhances T cell infiltration in the tumor microenvironment and therefore suppressing melanoma and NSCLC growth.